Highlights1,2
Continuing Operations:
Health, Nutrition & Bioscience delivered a solid performance in the first nine months with sales up 19% and organic sales growth of 10%
o Animal Nutrition & Health: +8% organic sales growth
o Health, Nutrition & Care: +10% organic sales growth
o Food & Beverage: +12% organic sales growth
Adjusted EBITDA up 6% reflecting continuing inflationary environment
Full Year outlook 2022 lowered: Adjusted EBITDA expected to increase by low single digits
Key figures - Continuing Operations
in € million Jan-Sept 2022 Jan-Sept 2021 % Change Volume Price/mix FX Other
Sales 6,297 5,341 18% 2% 7% 7% 2%
HNB 6,245 5,272 19% 2% 8% 7% 2%
ANH 2,814 2,430 16% -1% 9% 8% 0%
HNC 2,234 1,892 18% 4% 6% 8% 0%
FNB 1,158 917 26% 4% 8% 5% 9%
Adjusted EBITDA 1,102 1,040 6%
HNB 1,174 1,110
Corporate -72 -70
Adjusted EBITDA margin 17.5% 19.5%
HNB 18.8% 21.1%
Co-CEO statement
Geraldine Matchett and Dimitri de Vreeze, Co-CEOs, commented: “All our businesses delivered good organic growth during the third quarter. We continue to counter rising energy and raw material prices, which accelerated especially in Europe, albeit with a time lag. Market demand remained resilient across our three businesses in a challenging macro-economic environment.

Given the positive structural long-term drivers of our business, underpinned by progress on our strong pipeline of innovations, we are confident in the mid-term financial targets for DSM.

Since their announcements back in May, good progress has been made towards closing the divestment of DSM Engineering Materials to Advent International and LANXESS, and our forthcoming merger with Firmenich. These significant steps will lead to the establishment of DSM-Firmenich, a purpose-led leading creation and innovation partner in nutrition, beauty and well-being.”

Q3 Highlights
Continuing Operations:

Health, Nutrition & Bioscience delivered a solid quarter with sales up 20%, organic sales growth of 9% and Adjusted EBITDA up +3%
o Animal Nutrition & Health: +6% organic sales growth
o Health, Nutrition & Care: +11% organic sales growth
o Food & Beverage: +14% organic sales growth

Key figures - Continuing Operations

see Meer op
https://www.dsm.com/corporate/news/news-archive/2022/q3-2022-trading-update.html

and
Outlook 2022
DSM has lowered its full year 2022 outlook, and now expects its Adjusted EBITDA for Continuing Operations (Health, Nutrition & Bioscience and Corporate Activities) to increase by a low-single digits.